Business
Pacira BioSciences Appoints Samit Hirawat, M.D., to Board of Directors
-- Veteran Executive Brings More Than 25 Years of Clinical Development and Industry Expertise -- BRISBANE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Pacira
About this update from Pacira Biosciences, Inc.
[{"type":"text","content":"-- Veteran Executive Brings More Than 25 Years of Clinical Development and Industry Expertise -- BRISBANE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced the appointment of Samit Hirawat, M.D., to its Board of Directors. This appointment increases the size of the company’s Board of Directors to 10 members. “Samit is an accomplished and widely respected leader in the biopharmaceutical industry, and we are pleased to welcome him to our Board of Directors,” said Laura Brege, independent board chair of Pacira. “We believe his deep clinical development expertise and longstanding commitment to advancing innovative, patient‑centric therapies will make him an invaluable addition to our organization. We look forward to drawing on his insight and leadership as we accelerate the growth of our robust portfolio and pipeline of non‑opioid pain solutions and continue to elevate the standard of care for patients.” “I’m excited to be joining Pacira’s Board during this pivotal time in the Company’s evolution,” said Dr. Hirawat. “Pacira stands at the forefront of non‑opioid pain management, driven by an industry‑leading commercial portfolio and an exceptionally promising pipeline of innovative pain solutions, including next‑generation gene therapies. I look forward to collaborating with this talented leadership team and contributing my experience to help advance Pacira’s mission to fundamentally transform how pain is treated for patients around the world.” Most recently, Dr. Hirawat served as Chief Medical Officer, Executive Vice President, and Head of Global Drug Development at Bristol Myers Squibb, where he oversaw the worldwide clinical development portfolio and advanced multiple transformative therapies across therapeutic areas. Prior to that, he spent more than a decade at Novartis Pharmaceuticals in roles of increasing strategic and operational responsibility, culminating in his position as Executive Vice President and Head of Oncology Development. Dr. Hirawat earned his Bachelor of Medicine and Bachelor of Surgery (MBBS) from Sawai Man Singh Medical College, where he also trained as a Resident in General Surgery. He conducted his Internal Medicine residency and Medical...